Dr. Derek DiRocco Ph.D. serves as Independent Director of the Company. Dr. DiRocco has served as a member of our Board since April 2018. Dr. DiRocco has been a principal at RA Capital Management, LLC, an investment advisory firm that invests in healthcare and life science companies, since December 2017 and was previously an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015. Dr. DiRocco earned his Ph.D. in Pharmacology from the University of Washington and his B.A. in Biology from College of the Holy Cross. DiRocco is qualified to serve on our Board because of his experience as an investor in biotechnology companies and role in early stage companies.
As the Independent Director of 89bio Inc, the total compensation of Derek DiRocco at 89bio Inc is $6,667. There are 11 executives at 89bio Inc getting paid more, with Rohan Palekar having the highest compensation of $1,022,610.
Derek DiRocco is 39, he's been the Independent Director of 89bio Inc since 2018. There are 16 older and no younger executives at 89bio Inc. The oldest executive at 89bio Inc is Michael Hayden, 68, who is the Independent Director.
Derek's mailing address filed with the SEC is C/O 89BIO, INC., 142 SANSOME STREET, 2ND FLOOR, SAN FRANCISCO, CA, 94104.
Over the last 5 years, insiders at 89bio Inc have traded over $17,267,666 worth of 89bio Inc stock and bought 14,519,952 units worth $208,678,684 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ..., and Advisors Llc Orbi Med Capit.... On average, 89bio Inc executives and independent directors trade stock every 28 days with the average trade being worth of $2,197,340. The most recent stock trade was executed by Rohan Palekar on 1 April 2024, trading 52,718 units of ETNB stock currently worth $575,153.
89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.
89bio Inc executives and other stock owners filed with the SEC include: